MedTrace Logo

Statins for Treatment of Primary Intracerebral Hemorrhage

NCT07088250 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 264

Last updated 2025-07-28

No results posted yet for this study

Summary

The STOP ICH trial is a multicenter, prospective, randomized, open-label, blinded end-point (PROBE) study designed to assess the efficacy and safety of atorvastatin in patients with intracerebral hemorrhage (ICH) presenting within 3 to 24 hours of symptom onset.

Conditions

  • Cerebrovascular Disorders
  • Intracranial Hemorrhages
  • Intracranial Hemorrhage
  • Intracerebral Haemorrhage

Interventions

DRUG

Atorvastatin Treatment

Atorvastatin 20 mg once daily for 21 days.

OTHER

Best Medical Treatment

Patients in this group will receive best medical treatments in accordance with the guideline-directed management for ICH.

Sponsors & Collaborators

  • The Second Hospital of Anhui Medical University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-06
Primary Completion
2026-09-30
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07088250 on ClinicalTrials.gov